Human Herpes Virus-6 - T Cell Therapy: A Shifting Landscape

• Published in: Viruses Vol. 16; no. 4
• Main Authors: Kampouri, Eleftheria, Handley, Guy, Hill, Joshua A
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.04.2024
• Subjects: Analysis; Antigens; Chromosomes; Cytomegalovirus infections; Encephalitis; Epidemiology; Genomes; Genomics; Health aspects; Hematopoietic stem cells; Herpesviruses; Methods; T cells; Transplantation; Switzerland
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v16040498

HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant (HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following HCT and is associated with pleiotropic manifestations in this setting, including graft-versus-host disease, myelosuppression, pneumonitis, and CMV reactivation, although the causal link is not always clear. When the virus inserts its genome in chromosomes of germ cells, the chromosomally integrated form (ciHHV6) is inherited by offspring. The condition of ciHHV6 is characterized by the persistent detection of HHV-6 DNA, often confounding diagnosis of reactivation and disease—this has also been associated with adverse outcomes. Recent changes in clinical practice in the field of cellular therapies, including a wider use of post-HCT cyclophosphamide, the advent of letermovir for CMV prophylaxis, and the rapid expansion of novel cellular therapies require contemporary epidemiological studies to determine the pathogenic role and spectrum of disease of HHV-6B in the current era. Research into the epidemiology and clinical significance of HHV-6B in chimeric antigen receptor T cell (CAR-T cell) therapy recipients is in its infancy. No controlled trials have determined the optimal treatment for HHV-6B. Treatment is reserved for end-organ disease, and the choice of antiviral agent is influenced by expected toxicities. Virus-specific T cells may provide a novel, less toxic therapeutic modality but is more logistically challenging. Preventive strategies are hindered by the high toxicity of current antivirals. Ongoing study is needed to keep up with the evolving epidemiology and impact of HHV-6 in diverse and expanding immunocompromised patient populations.